Preclinical evaluation of oncolytic potential human rotavirus Wt 1-5 in gastric adenocarcinoma.
Henry Sossa-RojasPedro Gabriel Franco-MazCarlos Zapata-AcevedoLuz Dary Castañeda-CastañedaCarlos GuerreroPublished in: PloS one (2023)
Despite advances in biomedical research, gastric cancer remains the leading cause of morbidity and mortality worldwide due to the limited efficacy of conventional therapies. In recent decades, oncolytic viruses have emerged as a biological therapeutic alternative to cancer due to their selectivity, effectiveness, and low toxicity. However, clinical trials have shown that developing a virus with selectivity for multiple tumor receptors and the ability to penetrate and diffuse through the tumor microenvironment to reactivate the immune system remains challenging. This study aimed to examine the oncolytic potential of tumor cell-adapted rotavirus Wt1-5 in gastric adenocarcinoma samples. This study focused on determining the propagation capacity of the RV Wt1-5 through the tumor and the importance of the expression of cell surface co-receptors, including integrin β3, protein disulfide isomerase (PDI), and heat shock proteins (Hsp-90, -70, -60, -40, and Hsc 70), during infection of tumor cells. These proteins were found to be differentially expressed in tumor cells compared to adjacent non-tumor cells. Preincubation of gastric tumor cells with antibodies against these proteins decreased rotavirus infections, validating their importance in the binding and entry of RV Wt1-5 into tumor cells, as previously reported. Upon RV infection, apoptosis was one of the types of death that was observed. This was evidenced by evaluating the expression of CASP-3, -9, PARP, cytochrome C, Bax, Bid, p53, and Bcl-2, as well as observing morphological changes such as chromatin margination, nuclear condensation, and fragmentation. Finally, at 60 h.p.i, histological analysis revealed that oncolysis compromised the entire thickness of the tumor. Therefore, the results suggest that RV Wt1-5 could be a novel therapeutic agent co-adjuvant agent for conventional and targeted therapies in managing GC. Ex vivo infection of the tumor tissue model showed characteristics of an immune response that could be explored in future studies.
Keyphrases
- mycobacterium tuberculosis
- heat shock
- immune response
- clinical trial
- poor prognosis
- squamous cell carcinoma
- cell surface
- single cell
- systematic review
- gene expression
- binding protein
- cell proliferation
- heat shock protein
- transcription factor
- induced apoptosis
- endoplasmic reticulum stress
- dna methylation
- mass spectrometry
- cell death
- toll like receptor
- inflammatory response
- endothelial cells
- optical coherence tomography
- open label
- locally advanced
- radiation therapy
- high resolution
- bone marrow
- amino acid
- signaling pathway
- gas chromatography
- squamous cell